US Patent

US8703787 — Methods of using ALK inhibitors

Method of Use · Assigned to IRM LLC · Expires 2032-02-02 · 6y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for using certain compounds to treat EML4-ALK+ non-small cell lung cancer, including cases resistant to crizotinib.

USPTO Abstract

The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK + mediated condition such as EML4-ALK + non-small cell lung cancer, and optionally resistant to crizotinib; wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined above.

Drugs covered by this patent

Zykadia (ceritinib) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1179`	—	Zykadia
`U-1179`	—	Zykadia

Patent Metadata

Patent number: US8703787
Jurisdiction: US
Classification: Method of Use
Expires: 2032-02-02
Drug substance claim: No
Drug product claim: No
Assignee: IRM LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.